[1]
|
Norwood, D.A., Montalvan-Sanchez, E., Dominguez, R.L., et al. (2022) Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment. Gastroenterology Clinics of North America, 51, 501-518.
https://doi.org/10.1016/j.gtc.2022.05.001
|
[2]
|
Chen, Q., Yu, L., Hao, C.Q., et al. (2016) Effectiveness of Endo-scopic Gastric Cancer Screening in a Rural Area of Linzhou, China: Results from a Case-Control Study. Cancer Medi-cine, 5, 2615-2622. https://doi.org/10.1002/cam4.812
|
[3]
|
Tebbutt, N., Pedersen, M.W. and Johns, T.G. (2013) Targeting the ERBB Family in Cancer: Couples Therapy. Nature Reviews Cancer, 13, 663-673. https://doi.org/10.1038/nrc3559
|
[4]
|
Gravalos, C. and Jimeno, A. (2008) HER2 in Gastric Cancer: A New Prog-nostic Factor and a Novel Therapeutic Target. Annals of Oncology, 19, 1523-1529. https://doi.org/10.1093/annonc/mdn169
|
[5]
|
Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. https://doi.org/10.1038/sj.onc.1210477
|
[6]
|
Yuan, J., Dong, X., Yap, J. and Hu, J. (2020) The MAPK and AMPK Signalings: Interplay and Implication in Targeted Cancer Therapy. Journal of Hematology & Oncology, 13, Article No. 113.
https://doi.org/10.1186/s13045-020-00949-4
|
[7]
|
Vakiani, E. (2015) HER2 Testing in Gastric and Gastroesopha-geal Adenocarcinomas. Advances in Anatomic Pathology, 22, 194-201. https://doi.org/10.1097/PAP.0000000000000067
|
[8]
|
Abrahao-Machado, L.F. and Scapulatempo-Neto, C. (2016) HER2 Testing in Gastric Cancer: An Update. World Journal of Gastroenterology, 22, 4619-4625. https://doi.org/10.3748/wjg.v22.i19.4619
|
[9]
|
Huang, D., Li, Z.S., Fan, X.S., et al. (2018) HER2 Status in Gastric Adenocarcinoma of Chinese: A Multicenter Study of 40842 Patients. Chinese Journal of Pathology, 47, 822-826.
|
[10]
|
中国临床肿瘤学会乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会. 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版) [J]. 中华医学杂志, 2021, 101(17): 1226-1231.
|
[11]
|
Van Cutsem, E., Bang, Y.J., et al. (2015) HER2 Screening Data from ToGA: Targeting HER2 in Gastric and Gastroesophageal Junction Cancer. Gastric Cancer, 18, 476-484. https://doi.org/10.1007/s10120-014-0402-y
|
[12]
|
Belmonte, F.R., Martin, J.L., et al. (2016) Digital PCR Methods Improve Detection Sensitivity and Measurement Precision of Low Abundance mtDNA Deletions. Scientific Reports, 6, Article No. 25186.
https://doi.org/10.1038/srep25186
|
[13]
|
Cheng, M.L., Pectasides, E., Hanna, G.J., et al. (2021) Circulating Tumor DNA in Advanced Solid Tumors: Clinical Relevance and Future Directions. CA: A Cancer Journal for Clinicians, 71, 176-190.
https://doi.org/10.3322/caac.21650
|
[14]
|
Roviello, G., Catalano, M., Iannone, L.F., et al. (2022) Current Status and Future Perspectives in HER2 Positive Advanced Gastric Cancer. Clinical and Translational Oncology, 24, 981-996.
https://doi.org/10.1007/s12094-021-02760-0
|
[15]
|
刘厚聪, 周和凯, 王纪东, 等. 数字PCR检测循环肿瘤DNA中HER2基因扩增对胃癌的预后评估[J]. 分子诊断与治疗杂志, 2023, 15(3): 368-372. https://doi.org/10.19930/j.cnki.jmdt.2023.03.020
|
[16]
|
Lin, D., Shen, L., Luo, M., et al. (2021) Circulating Tumor Cells: Biology and Clinical Significance. Signal Transduction and Targeted Therapy, 6, Article No. 404. https://doi.org/10.1038/s41392-021-00817-8
|
[17]
|
Yap, T.A., Lorente, D., Omlin, A., et al. (2014) Circulating Tu-mor Cells: A Multifunctional Biomarker. Clinical Cancer Research, 20, 2553-2568. https://doi.org/10.1158/1078-0432.CCR-13-2664
|
[18]
|
Nanou, A., Zeune, L.L., Bidard, F.C., et al. (2020) HER2 Expression on Tumor-Derived Extracellular Vesicles and Circulating Tumor Cells in Metastatic Breast Cancer. Breast Cancer Research, 22, Article No. 86.
https://doi.org/10.1186/s13058-020-01323-5
|
[19]
|
Rakhshani, N., Kalantari, E., Bakhti, H., et al. (2014) Evaluation of HER-2/Neu Overexpression in Gastric Carcinoma Using a Tissue Microarray. The Asian Pacific Journal of Cancer Prevention, 15, 7597-7602.
https://doi.org/10.7314/APJCP.2014.15.18.7597
|
[20]
|
Chen, R., Zhou, X., Liu, J. and Huang, G. (2016) Relation-ship between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. Journal of Nuclear Medicine, 57, 1040-1044. https://doi.org/10.2967/jnumed.115.171165
|
[21]
|
Ahadi, M., Moradi, A., Musavinejad, L., et al. (2020) The Expression of p53, CD44, Ki-67, and HER-2/Neu Markers in Gastric Cancer and Its Association with Histopatho-logical Indicators: A Retrospective Study. The Asian Pacific Journal of Cancer Prevention, 21, 1607-1614. https://doi.org/10.31557/APJCP.2020.21.6.1607
|
[22]
|
袁绍斌, 曹小萌, 夏天红, 等. 胃癌临床病理特征与HER2表达的相关性研究[J]. 医学信息, 2022, 35(24): 50-54.
|
[23]
|
Geng, Y., Chen, X., Qiu, J., Zhou, Y., Wang, J., Liu, L., Shao, Y. and Yin, Y. (2014) Human Epidermal Growth Factor Receptor-2 Expression in Primary and Metastatic Gastric Cancer. International Journal of Clinical Oncology, 19, 303-311. https://doi.org/10.1007/s10147-013-0542-9
|
[24]
|
Ray, A. (2017) Tumor-Linked HER2 Expression: Association with Obesity and Lipid-Related Microenvironment. Hormone Molecular Biology and Clinical Investigation, 32, Article ID: 20170020.
https://doi.org/10.1515/hmbci-2017-0020
|
[25]
|
刘江, 李建刚, 李亮, 等. 肥胖对腹腔镜辅助胃癌手术近期疗效及HER2状态的影响[J]. 现代医药卫生, 2023, 39(14): 2357-2362.
|
[26]
|
姜晨霞, 黄华. HER-2在胃癌中的表达及临床意义[J]. 交通医学, 2023, 37(3): 252-254+258.
https://doi.org/10.19767/j.cnki.32-1412.2023.03.006
|
[27]
|
刘洋, 高剑波, 岳松伟, 等. CT强化率、灌注参数与胃癌病灶中HER2表达的关系[J]. 世界华人消化杂志, 2015, 23(3): 426-431.
|
[28]
|
郑红伟, 彭晓博, 郑凌云, 等. 胃癌CT征象与HER2基因表达的相关性研究[J]. 中国CT和MRI杂志, 2021, 19(1): 161-164.
|
[29]
|
刘洋, 高剑波, 岳松伟, 等. 胃癌 MSCT表现与HER2基因表达情况的相关性研究[J]. 实用放射学杂志, 2015(3): 427-430. https://doi.org/10.3969/j.issn.1002-1671.2015.03.021
|
[30]
|
潘圣宝, 雷振. 进展期胃癌多层螺旋CT表现与HER2表达的相关性[J]. 中国医学影像学杂志, 2019, 27(4): 282-285.
|
[31]
|
Jørgensen, J.T. and Hersom, M. (2012) HER2 as a Prognostic Marker in Gastric Cancer—A Systematic Analysis of Data from the Literature. Journal of Cancer, 3, 137-144. https://doi.org/10.7150/jca.4090
|
[32]
|
蔡妙田, 孟巍, 姜智允, 等. 胃癌MSCT表现与HER-2表达的关系[J]. 现代肿瘤医学, 2018, 26(6): 908-910.
|
[33]
|
赵瑾, 陈海燕, 丁信法, 等. 胃癌MSCT表现和临床病理特征与HER2表达的相关性研究[J]. 实用肿瘤杂志, 2020, 35(3): 201-207. https://doi.org/10.13267/j.cnki.syzlzz.2020.03.002
|
[34]
|
张旭, 南京柱, 栾小娟, 等. 血清细胞角质素片段19在胃癌患者中的表达及对HER-2阳性的预测能力[J]. 解放军医学院学报, 2023, 44(5): 495-500.
|
[35]
|
Wang, S.H., Sun, Y.F., Liu, Y., et al. (2015) CT Contrast Enhancement Correlates with Pathological Grade and Microvessel Density of Pancreatic Cancer Tissues. International Journal of Clinical and Experimental Pathology, 8, 5443-5449.
|
[36]
|
安岁萌. 双源双能CT多参数定量与胃腺癌的相关性研究[D]: [硕士学位论文]. 西安: 西安医学院, 2020.
https://doi.org/10.27909/d.cnki.gxaxy.2020.000015
|
[37]
|
谢聿娟, 张德健. 双源双能CT多定量参数与胃癌患者术前分期及肿瘤因子相关性分析[J]. 中国CT和MRI杂志, 2022, 20(2): 130-133.
|
[38]
|
He, J., Shi, H., Zhou, Z., et al. (2015) Correlation between Apparent Diffusion Coefficients and HER2 Status in Gastric Cancers: Pilot Study. BMC Cancer, 15, Article No. 749. https://doi.org/10.1186/s12885-015-1726-7
|
[39]
|
王铮, 苏丹柯, 赖少侣, 等. 胃癌MRI非形态学表征与Her-2表达水平的相关性分析[J]. 临床放射学杂志, 2019, 38(2): 281-285. https://doi.org/10.13437/j.cnki.jcr.2019.02.024
|
[40]
|
王姣, 次旦旺久, 卢海燕, 等. 胃癌DWI ADC值与HER-2、CEA表达的相关性分析[J]. 现代肿瘤医学, 2020, 28(21): 3749-3752.
|
[41]
|
Chen, R., Zhou, X., Liu, J., et al. (2016) Relationship between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. Journal of Nuclear Medicine, 57, 1040-1044. https://doi.org/10.2967/jnumed.115.171165
|
[42]
|
弭丽丽, 殷飞, 雷连会, 等. 18F-FDG PET/CT相关参数与胃癌患者HER2表达状态的相关性研究[J]. 中国肿瘤临床, 2021, 48(6): 301-305.
|
[43]
|
王建林, 史爱琪, 范丑丑, 等. 18F-FDG PET/CT代谢参数和代谢异质性与胃癌患者人表皮生长因子受体2表达状态的相关性[J]. 中国医学科学院学报, 2022, 44(4): 628-635.
|
[44]
|
张健楠, 刘洋, 高剑波, 等. PET-CT最大标准摄取值定量评估胃癌组织中HER2的表达情况[J]. 世界华人消化杂志, 2016, 24(15): 2312-2318.
|
[45]
|
Park, J.S., Lee, N., Beom, S.H., et al. (2018) The Prognostic Value of Volume-Based Parameters Using 18F-FDG PET/CT in Gastric Cancer According to HER2 Status. Gastric Cancer, 21, 213-224.
https://doi.org/10.1007/s10120-017-0739-0
|
[46]
|
王书兴, 张晗, 陈奕晴, 等. 基于CT影像组学结合机器学习模型预测食管胃结合部腺癌人表皮生长因子受体2状态[J]. 中国医学影像技术, 2022, 38(3): 398-402. https://doi.org/10.13929/j.issn.1003-3289.2022.03.018
|
[47]
|
张昊辰, 邱炳江, 崔艳芬, 等. 基于深度学习的CT影像预测胃癌HER2状态[J]. 暨南大学学报(自然科学与医学版), 2023, 44(1): 78-86.
|
[48]
|
Ma, T., Cui, J., Wang, L., et al. (2022) A Multiphase Contrast-Enhanced CT Radiomics Model for Prediction of Human Epidermal Growth Factor Receptor 2 Status in Advanced Gastric Cancer. Frontiers in Genetics, 13, Article ID: 968027. https://doi.org/10.3389/fgene.2022.968027
|
[49]
|
Liu, Q., Li, J., Xin, B., et al. (2023) Preoperative 18F-FDG PET/CT Radiomics Analysis for Predicting HER2 Expression and Prognosis in Gastric Cancer. Quantitative Imaging in Medicine and Surgery, 13, 1537-1549.
https://doi.org/10.21037/qims-22-148
|